These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1071 related items for PubMed ID: 26498143

  • 1. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, Völker B, Schacht V, Timmermann B, Gutzmer R.
    Oncotarget; 2015 Nov 10; 6(35):37895-905. PubMed ID: 26498143
    [Abstract] [Full Text] [Related]

  • 2. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ.
    Diagn Mol Pathol; 2012 Mar 10; 21(1):1-8. PubMed ID: 22306669
    [Abstract] [Full Text] [Related]

  • 3. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G, Dudley J, Tseng LH, Smith K, Gurda GT, Gocke CD, Eshleman JR, Lin MT.
    Hum Pathol; 2015 Jan 10; 46(1):113-9. PubMed ID: 25456393
    [Abstract] [Full Text] [Related]

  • 4. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG.
    Semin Cutan Med Surg; 2012 Dec 10; 31(4):267-73. PubMed ID: 23174497
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, Lundgren L, Ingvar C, Jönsson G.
    Br J Dermatol; 2013 Nov 10; 169(5):1049-55. PubMed ID: 23855428
    [Abstract] [Full Text] [Related]

  • 7. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
    Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R, Merkelbach-Bruse S.
    BMC Cancer; 2014 Jan 10; 14():13. PubMed ID: 24410877
    [Abstract] [Full Text] [Related]

  • 8. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA.
    Br J Cancer; 2016 Mar 29; 114(7):801-8. PubMed ID: 26924424
    [Abstract] [Full Text] [Related]

  • 9. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
    Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, Kovach B, Lee JR, Ochoa P, Langland R, Halait H, Lawrence HJ, Dugan MC.
    Arch Pathol Lab Med; 2012 Nov 29; 136(11):1385-91. PubMed ID: 22332713
    [Abstract] [Full Text] [Related]

  • 10. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M, Habib RH, Gerges R, Saab J, Loya A, Amr SS, Sheikh S, Satti M, Oberkanins C, Khalifeh I.
    Exp Mol Pathol; 2014 Dec 29; 97(3):315-20. PubMed ID: 25236573
    [Abstract] [Full Text] [Related]

  • 11. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.
    J Clin Oncol; 2011 Apr 01; 29(10):1239-46. PubMed ID: 21343559
    [Abstract] [Full Text] [Related]

  • 12. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.
    Ponti G, Pellacani G, Tomasi A, Gelsomino F, Spallanzani A, Depenni R, Al Jalbout S, Simi L, Garagnani L, Borsari S, Conti A, Ruini C, Fontana A, Luppi G.
    J Clin Pathol; 2013 May 01; 66(5):441-5. PubMed ID: 23463675
    [Abstract] [Full Text] [Related]

  • 13. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
    Ponti G, Tomasi A, Maiorana A, Ruini C, Maccaferri M, Cesinaro AM, Depenni R, Manni P, Gelsomino F, Giusti F, Garagnani L, Pellacani G.
    Appl Immunohistochem Mol Morphol; 2016 Jan 01; 24(1):30-4. PubMed ID: 26633701
    [Abstract] [Full Text] [Related]

  • 14. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
    Nardin C, Puzenat E, Prétet JL, Algros MP, Doussot A, Puyraveau M, Mougin C, Aubin F.
    Melanoma Res; 2015 Aug 01; 25(4):328-34. PubMed ID: 26020488
    [Abstract] [Full Text] [Related]

  • 15. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B, Kandiloğlu G, Akalin T.
    Am J Dermatopathol; 2016 Feb 01; 38(2):113-20. PubMed ID: 26630683
    [Abstract] [Full Text] [Related]

  • 16. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
    Uguen A, Guéguen P, Legoupil D, Bouvier S, Costa S, Duigou S, Lemasson G, Ledé F, Sassolas B, Talagas M, Férec C, Le Maréchal C, De Braekeleer M, Marcorelles P.
    Hum Pathol; 2015 Nov 01; 46(11):1582-91. PubMed ID: 26297254
    [Abstract] [Full Text] [Related]

  • 17. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV.
    Eur J Cancer; 2013 Mar 01; 49(5):1073-9. PubMed ID: 23237741
    [Abstract] [Full Text] [Related]

  • 18. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A, Talagas M, Costa S, Samaison L, Paule L, Alavi Z, De Braekeleer M, Le Marechal C, Marcorelles P.
    Diagn Pathol; 2015 Jul 25; 10():121. PubMed ID: 26204954
    [Abstract] [Full Text] [Related]

  • 19. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.
    Manfredi L, Meyer N, Tournier E, Grand D, Uro-Coste E, Rochaix P, Brousset P, Lamant L.
    Acta Derm Venereol; 2016 Jun 15; 96(5):630-4. PubMed ID: 26695089
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.
    Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA.
    Cancer; 2017 Apr 15; 123(8):1372-1381. PubMed ID: 27911979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.